Evidence map›Paper›PMID 29876671›Full record

ArticleWorld journal of urology2019

Validating the role of ABO blood type in risk of perioperative venous thromboembolism after radical cystectomy.

Sumeet Bhanvadia, Kayvan Kazerouni, Soroush T Bazargani, Gus Miranda, Jie Cai, Siamak Daneshmand, Hooman Djaladat

Abstract read
PubMed Publisher
In one paragraph

Article in World journal of urology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Sarcopenia as an independent predictor for venous thromboembolism events in bladder cancer patients undergoing radical cystectomy.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sumeet BhanvadiaNorris Comprehensive Cancer Center, USC Institute of Urology, Los Angeles, CA, USA.
Kayvan KazerouniUSC School of Medicine, Norris Comprehensive Cancer Center, USC Institute of Urology, Los Angeles, CA, USA.
Soroush T BazarganiNorris Comprehensive Cancer Center, USC Institute of Urology, Los Angeles, CA, USA.
Gus MirandaNorris Comprehensive Cancer Center, USC Institute of Urology, Los Angeles, CA, USA.
Jie CaiNorris Comprehensive Cancer Center, USC Institute of Urology, Los Angeles, CA, USA.
Siamak DaneshmandNorris Comprehensive Cancer Center, USC Institute of Urology, Los Angeles, CA, USA.
Hooman DjaladatNorris Comprehensive Cancer Center, USC Institute of Urology, Los Angeles, CA, USA. djaladat@med.usc.edu.ORCID http://orcid.org/0000-0002-1984-3556

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo validate the relationship between ABO blood type and risk of VTE post-RC in a large retrospective database.

methodsPatients with urothelial bladder cancer (UBC) who underwent RC (intent-to-cure) for whom ABO blood type was available between 2003 and 2015 were identified from our IRB-approved database. VTE was defined as deep vein thrombosis (DVT) or pulmonary embolism (PE) within 90 days of surgery. VTE prophylaxis consisted of immediate postoperative Coumadin (2003-2009), unfractionated heparin (UFH) during hospitalization (2009-2015), and UFH during hospitalization plus 4 weeks of enoxaparin after discharge (2013-2015). Univariable and multivariable analyses of the association of ABO blood type with postoperative, symptomatic VTE and oncologic outcomes were performed.

resultsOf 1341 patients, 595 (44.4%) were ABO type O and 746 (55.6%) were non-O (A, B and AB). 90 patients were diagnosed with VTE within 90 days of surgery (6.7%) (43% DVT-only, 57% PE ± DVT). On multivariable analysis non-O blood type was associated with a nearly twofold increased risk of VTE (OR = 1.94, 95% CI 1.215-3.098, p = 0.004). No difference in recurrence-free survival or overall survival was seen between ABO groups.

conclusionNon-O blood type is an independent, non-modifiable risk factor for postoperative VTE after RC. More comprehensive counseling and thromboprophylaxis should be considered in this high-risk group.

Indexed as

ABO Blood-Group SystemAgedCystectomyFemaleHumansMalePostoperative ComplicationsRetrospective StudiesRisk FactorsUrinary Bladder NeoplasmsVenous ThromboembolismABO Blood-Group SystemBladderCystectomyMeSHThromboprophylaxisUrothelial carcinomaVenous thromboembolism

Identifiers

PMID29876671

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.